Ozempic in Pro-Eating-Disorder Communities

A study published in the International Journal of Eating Disorders on 16 August 2026 gives the first structured look at how a pro-eating-disorder community on X (formerly Twitter) talks about Ozempic^[1]. Researchers Daisy Sun, Tovah Yanover, Helena Katona and Jennifer Couturier collected 451 public tweets containing both "Ozempic" and "edtwt" (the community's own hashtag) posted between August 2024 and July 2025, then applied structured content analysis to the 255 tweets that met their inclusion criteria^[1]. The paper does not reproduce the posts themselves. It classifies what they discuss, at the level of theme and sub-theme, so that clinicians and platforms can see the shape of the problem without the underlying content being restated.

What the study found

Two independent reviewers sorted the 255 qualifying tweets into three categories^[1]. Personal narratives, meaning posts expressing curiosity (19.2%), a stated desire to use the drug (11.8%), questions about access (9.0%), or reports of active use (11.4%), made up just over half the sample. Attitudes and perceptions, split between normalization of Ozempic as a weight-loss tool (28.6%), ethical judgment of its use (8.2%), and outright rejection of it (8.2%), made up roughly 45%. Information sharing, including posts that carried risk warnings rather than encouragement, accounted for only 3.5%.

The authors' own summary is direct: "Ozempic is actively integrated within pro-ED discourse on X, where discussions often normalize its use for weight loss and express sustained interest in its use"^[1]. The imbalance is the headline finding. Content that normalizes or expresses interest in using a prescription medicine for disordered-eating purposes outweighed content warning about risk by roughly thirteen to one.

Why Ozempic specifically

Ozempic is a brand name for semaglutide, a GLP-1 receptor agonist approved for type-2 diabetes, with its sister brand Wegovy approved for chronic weight management. The mechanism that makes it effective in those approved indications, reduced appetite and prolonged fullness through delayed gastric emptying, is the same mechanism that makes it attractive to a community organized around restricting food intake. That overlap is not hypothetical. A separate research letter in JAMA Psychiatry, published in June 2026, surveyed 436 US adults with a diagnosed eating disorder and found that 140 (32.1%) reported lifetime use of a GLP-1 receptor agonist and 96 (22.0%) reported current use^[2]. Use was highest among people with binge eating disorder and lowest among people with anorexia nervosa, and 44 respondents (10.1%) reported using the medication in ways their prescriber had not intended, while 43 (9.9%) reported using a compounded rather than a brand-name product^[2]. The study authors describe eating-disorder patients as "a clinically diverse population who may be consuming GLP-1 RAs in contraindicated ways to maintain eating disorder psychopathology through rapid restriction and weight loss."

What this research does not show

The netnographic study is a content analysis of public posts, not a clinical trial and not a survey of how many people with eating disorders actually obtain or take semaglutide. It cannot establish that any single tweet reflects a real prescription, a real purchase, or a real medical outcome. The sample is also small and platform-specific: 255 tweets from one hashtag community on one platform over one year is not a representative measure of how widely this framing has spread across other platforms or languages. What the study does establish, credibly, is that within this specific community the public conversation leans toward normalizing rather than warning against the drug's use for disordered-eating purposes.

What eating-disorder organizations already advise

The National Association of Anorexia Nervosa and Associated Disorders (ANAD) has published clinical guidance specifically on GLP-1 medications and eating disorders, and it treats current or recent restrictive, bingeing, or purging behavior, active anorexia nervosa or atypical anorexia nervosa, and unstable recovery as situations that warrant particular caution before starting a GLP-1 medication^[3]. ANAD's stated concern is mechanical: recovery from an eating disorder depends on re-learning hunger and fullness cues, and a medication that suppresses appetite can work directly against that process, while rapid weight loss and gastrointestinal side effects can themselves function as relapse triggers^[3]. No GLP-1 medication, including semaglutide, carries FDA approval for treating an eating disorder. Where a prescriber and patient with an eating-disorder history do decide to proceed, ANAD's guidance calls for a multidisciplinary team, regular standardized monitoring, and an exit plan agreed before treatment starts, not a decision made outside clinical supervision.

Why this matters

Semaglutide is a prescription-only medicine everywhere PeptideMethods covers regulation, and it is not authorized anywhere as a treatment for anorexia, bulimia, or other restrictive eating disorders. The concern researchers are raising is not about the drug's approved use. It is about a mismatch between a drug's real pharmacology and how a vulnerable community online talks about it, at a moment when GLP-1 medicines are widely visible, widely discussed, and in places obtainable outside a prescriber's oversight. Sun and colleagues frame their finding as a case for monitoring, not alarm, and that framing is worth keeping: the paper documents a pattern in public discourse, and that pattern is a reason for clinicians, platforms, and family members to pay closer attention, not a diagnosis of any individual reader.

If you or someone you know is struggling with disordered eating, the ANAD Helpline is reachable at (888) 375-7767, Monday through Friday, 9am to 9pm CST, for treatment referrals and support^[3]. This article is for educational and journalistic purposes only and is not medical advice. Decisions about starting, continuing, or stopping any GLP-1 medication, including for someone with a history of disordered eating, belong with a treating clinician who knows the individual's full history.